Chemotherapy and Treatment Outcomes in Bloom's Syndrome
Persons with Bloom's syndrome are at higher risk of developing cancer in their lifetimes. The increased risk of cancer includes cancers of many different sites and types, and there is a shift toward younger age of diagnosis relative to the median cancer-specific age of diagnosis in the general population. Chemotherapeutic treatments of cancer in Bloom's syndrome must take into account hypersensitivities to DNA-damaging agents that are part of conventional cancer treatment regimens, which can result in severe destruction of bowel mucosa and the bone marrow. Specific dosage recommendations have not been possible, and more information regarding cancer treatment outcomes is needed.
Investigators at Radboud University Nijmegen Medical Centre in the Netherlands in cooperation with the Bloom Syndrome Foundation (Europe) have initiated a study to understand better the relationship between chemotherapy and treatment outcomes in Bloom's syndrome. These investigators are seeking medical records from Bloom's syndrome patients who have had a cancer diagnosis. The objective of the study is to optimize the treatment of cancer in Bloom's syndrome. To participate in this study or learn more about it, please contact the Bloom Syndrome Foundation (Europe) at firstname.lastname@example.org
Similar work is being conducted under the auspices of the Bloom's Syndrome Registry, where medical records from more than 250 persons with Bloom's syndrome have been assembled over the last 50 years and the natural history of the syndrome has been carefully chronicled.